Regenbogen Co., Ltd.(President Jun Sung Park, www.iregenbogen.com) an Aesthetic Medical Device company will show their new Hybrid Filler of PLA(Poly D,L-lactic) & HA(Sodium Hyaluronate) which name is 'Etrebelle' at KIMES 2019 in Seoul, Korea on March 14-17, 2019.
'Etrebelle' is a Hybrid Filler of PLA(Poly D, L-lactide) microparticles
and HA(Sodium Hyaluronate) which are approved by US FDA as biocompatible,
biodegradable polymer materials, for providing immediate physical improvement
of facial wrinkle and long lasting elasticity by stimulating collagenesis.
This product has been approved by KFDA(license no. 17-972) as
graft/prosthesis and tested in clinical trials by Leaders clinic(Dr. Youn),
Cellpark clinic(Dr. Chung), Picaso clinic(Dr. Kim) and so on to prove its
differentiated efficacy from existing HA filler.
To control the treatment level and indication, 'Etrebelle' is consisted of
'Etrebelle 200mg' and 'Etrebelle 50mg' models. From this, Regenbogen Co., Ltd.
is going to hold regular live seminars about complex application of its newly
introduced filler with thread lifting as a major part.
Regenbogen Co., Ltd. is an
aesthetic medical device company providing optimum quality product with
corresponding educational seminar not only internally in Korea, but throughout
China, Japan, Southeast Asia, Europe and Middle East from 2012.